NCT01605825

A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 83 (actual)
• Sponsor: Acorda Therapeutics · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, safety and tolerability study in subjects with chronic stable sensorimotor deficits after ischemic stroke. It has been designed as a double-blind, placebo-controlled, 2-period crossover study.

Conditions

• Ischemic Stroke

Interventions

Type	Name	Description
DRUG	placebo/dalfampridine-ER	Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
DRUG	dalfampridine-ER/placebo	Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart

Timeline

• Start date: 2012-05-01
• Primary completion: 2013-02-01
• Completion: 2013-03-01
• First posted: 2012-05-25
• Last updated: 2016-01-22
• Results posted: 2014-03-10

Locations

20 sites across 1 country: United States